Stonegate Capital Partners has updated its coverage on Alpha Cognition Inc. (NASDAQ: ACOG) following the company's first full quarter of ZUNVEYL® commercialization. This period saw significant early adoption in the U.S. long-term care market and a key regulatory milestone in China. ZUNVEYL has been ordered in over 300 long-term care facilities with 65% placing repeat orders. Additionally, Alpha Cognition secured its first national Medicare Part D contract, enhancing patient access. For more details, visit newsfilecorp.com/release/177020.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.